Skip to main content

Table 1 Subjects characteristics

From: A new nucleosomic-based model to identify and diagnose SSc-ILD

  SSc (n = 67) SSc-ILD (n = 31)
Age, years 56 ± 12 60 ± 13
Gender (M/F) 17/50 6/25
BMI, kg/m2 25 ± 4 25 ± 4
Smokers (NS/FS/S) (%) 48/28/24 55/28/17
Paq-year 15 ± 17 6.9 ± 8.4
CRP 1.7 (0.7-5.1) 2.4 (1.1-6.1)
FEV1 post-BD, % pred 98 ± 22 88 ± 23*
FVC post-BD, % pred 104 ± 20 90 ± 22**
FEV1/FVC post-BD, % pred 78 ± 10 81 ± 8
TLC, % pred 101 ± 15 85 ± 19***
TLCo % pred 71 ± 20 56 ± 16**
KCO % pred 79 ± 19 74 ± 14
HRT extent (% lung) / 5 (5-25)
IT, immunosupressive therapy (%) 14 38
OCS, oral cortico steroide (%) 24 28
Prednisolone equivalent (mg) 5 (5-5) 10 (5-10)
GI tract score, none/mild/severe (%)1 36/62/2 16/80/4
Disease duration (year) 6.93 ± 8.47 5.55 ± 5.87
Rodnan skin score 2 (0-5)° 2 (0-4)°
limited SSc/lcSSc/dSSc/sine scleroderma (%) 38/59/6.3/4.8 41/41/14/0
Musculoskeletal involvement (%) 22 21
Renal crisis (%) 6.8 0
Cardiac involvement (%) 2 37
  1. Data are expressed as mean ± SD
  2. NS non-smoker, FS former smoker, S smoker, IT immunosuppressive therapy (mycophenolate mofetil, methotrexate, cyclophosphamide), SSc systemic sclerosis, lcSSc limited cutaneous, dSSc diffuse cutaneous SSc, SS sine scleroderma
  3. °Values are expressed as mean ± SD when parametrics and median (IQR) when non parametrics
  4. 1GI tract score, missing value: SSc 20/67; SSc-ILD 12/31
  5. *p < 0.05
  6. **p < 0.01
  7. ***p < 0.001 compared to healthy subjects